1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,199 | 0,237 | 17:27 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cantargia to Participate in Upcoming Conferences | 141 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel... ► Artikel lesen | |
| 02.10. | Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer | 167 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 01.10. | Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC | 294 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this... ► Artikel lesen | |
| 11.09. | Cantargia Closes the Acquisition of CAN10 by Otsuka | 285 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's... ► Artikel lesen | |
| 29.08. | Cantargia im Q2 2025: Otsuka-Deal bringt 33 Mio. USD Sofortzahlung bei durchwachsenen klinischen Ergebnissen | 6 | Investing.com Deutsch | ||
| 29.08. | Cantargia Q2 2025 slides: Otsuka deal brings $33M upfront amid mixed clinical results | 2 | Investing.com | ||
| 27.08. | Cantargia Granted Important US Patent for Nadunolimab | 216 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent... ► Artikel lesen | |
| 21.08. | Cantargia: Aktie gibt trotz 630-Mio.-Dollar-Deal mit Otsuka nach | 5 | Investing.com Deutsch | ||
| 21.08. | Cantargia Publishes Half-Year Report 2025 | 315 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO with... ► Artikel lesen | |
| 18.08. | Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer | 348 | ACCESS Newswire | Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business... ► Artikel lesen | |
| 12.08. | Invitation to the Presentation of Cantargia's H1 2025 Report | 256 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August... ► Artikel lesen | |
| 17.07. | Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer | 422 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated... ► Artikel lesen | |
| 16.07. | Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer | 342 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival... ► Artikel lesen | |
| 15.07. | Otsuka to acquire Cantargia's CAN10 for autoimmune diseases | 4 | Pharmaceutical Technology | ||
| 15.07. | Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical | 445 | ACCESS Newswire | Cantargia receives an upfront cash payment of USD 33 million.Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments... ► Artikel lesen | |
| 17.06. | Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans | 337 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million... ► Artikel lesen | |
| 17.06. | Cantargia Q1 2025 slides: CAN10 advances amid funding challenges | 3 | Investing.com | ||
| 11.06. | Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation | 836 | ACCESS Newswire | Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development... ► Artikel lesen | |
| 19.05. | Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation | 272 | ACCESS Newswire | IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,... ► Artikel lesen | |
| 15.05. | Bulletin from the Annual General Meeting in Cantargia AB | 338 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge... ► Artikel lesen |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,60 | +0,55 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| EVOTEC | 6,976 | +1,60 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| QIAGEN | 42,375 | +0,25 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 500,00 | +0,85 % | Regeneron Says CHMP Recommends Libtayo For EU Approval As Adjuvant Treatment Of CSCC | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a... ► Artikel lesen | |
| BRAIN BIOTECH | 2,240 | +0,90 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.10.2025 / 15:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,014 | -0,39 % | XFRA CT9: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCARDIOL THERAPEUTICS... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,400 | -4,11 % | Burcon NutraScience Corporation: Burcon Pea and Sunflower Proteins Outperform in Plant-based Cheese Study | Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CSL | 120,16 | -2,15 % | Sanofi's $1.7B rare disease bet beats CSL's Zemaira in phase 2 face-off | ||
| MANNKIND | 4,827 | +2,22 % | MannKind: Stiller Gewinner im Kampf um die Lunge? | Nach einer Reihe operativer Fortschritte und der Übernahme von scPharmaceuticals richtet sich bei Aktionären der MannKind Corporation der Blick in die Zukunft. Die fundamentale Basis scheint geschaffen.... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,672 | +0,84 % | Oxford Nanopore Technologies: ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology | New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers
ViruSure, a global leader in pathogen safety testing for biopharmaceuticals... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,734 | -1,12 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,050 | -10,00 % | XFRA 473A: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILADAPTH.TH.SP.ADR6... ► Artikel lesen | |
| CODEXIS | 2,310 | +3,77 % | Codexis, Inc.: Codexis to Report Third Quarter 2025 Financial Results on November 6 | ||
| CORMEDIX | 9,600 | -1,54 % | CorMedix, Inc.: CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance | - Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million - Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million - Raising FY 2025 Pro Forma Net Revenue Guidance to at least $375... ► Artikel lesen |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,185 Euro und damit -2,12 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.